Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
123648163 | 12364816 | 3 | F | 2010 | 20160922 | 20160513 | 20160927 | EXP | US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-29301BP | BOEHRINGER INGELHEIM | 70.89 | YR | F | Y | 136.98000 | KG | 20160927 | OT | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
123648163 | 12364816 | 1 | PS | ATROVENT | IPRATROPIUM BROMIDE | 1 | Respiratory (inhalation) | 170 MCG | Y | 10005717 | 21527 | 34 | UG | NEBULISER LIQUID | |||||
123648163 | 12364816 | 2 | SS | ATROVENT | IPRATROPIUM BROMIDE | 1 | Respiratory (inhalation) | 8 ANZ | Y | 10005717 | 21527 | NEBULISER LIQUID | QID | ||||||
123648163 | 12364816 | 3 | SS | ATROVENT | IPRATROPIUM BROMIDE | 1 | Y | 10005717 | 21527 | ||||||||||
123648163 | 12364816 | 4 | C | CRESTOR | ROSUVASTATIN CALCIUM | 1 | Oral | 20 MG | 0 | 20 | MG | TABLET | QD | ||||||
123648163 | 12364816 | 5 | C | LISINOPRIL. | LISINOPRIL | 1 | Oral | 10 MG | 0 | 10 | MG | TABLET | QD | ||||||
123648163 | 12364816 | 6 | C | PREVICID | 2 | Oral | 30 MG | 0 | 30 | MG | CAPSULE | QD | |||||||
123648163 | 12364816 | 7 | C | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | Oral | 2000 MG | 0 | 1000 | MG | TABLET | BID | ||||||
123648163 | 12364816 | 8 | C | NOVOLOG | INSULIN ASPART | 1 | Subcutaneous | 66 U | 0 | 22 | IU | ||||||||
123648163 | 12364816 | 9 | C | LANTUS | INSULIN GLARGINE | 1 | Subcutaneous | 35 U | 0 | 35 | IU | ||||||||
123648163 | 12364816 | 10 | C | LEVOTHYROXINE. | LEVOTHYROXINE | 1 | Oral | 150 MG | 0 | 150 | MG | TABLET | QD | ||||||
123648163 | 12364816 | 11 | C | MAGNESIUM | MAGNESIUM | 1 | Oral | 400 MG | 0 | 400 | MG | TABLET | QD | ||||||
123648163 | 12364816 | 12 | C | CALCIUM PLUS | 2 | Oral | 1 ANZ | 0 | TABLET | QD | |||||||||
123648163 | 12364816 | 13 | C | BABY ASPIRIN | ASPIRIN | 1 | Oral | 1 ANZ | 0 | TABLET | QD | ||||||||
123648163 | 12364816 | 14 | C | Vitamin D 3 | 2 | Oral | 1000 U | 0 | 1000 | IU | CAPSULE | QD | |||||||
123648163 | 12364816 | 15 | C | VITAMIN E | .ALPHA.-TOCOPHEROL | 1 | Oral | 0 | QD | ||||||||||
123648163 | 12364816 | 16 | C | BIOTIN | BIOTIN | 1 | Oral | 10000 MCG | 0 | 10000 | UG | TABLET | QD | ||||||
123648163 | 12364816 | 17 | C | CHLORPHENIRAMINE MALEATE. | CHLORPHENIRAMINE MALEATE | 1 | Oral | 4 MG | 0 | 4 | MG | TABLET | QD | ||||||
123648163 | 12364816 | 18 | C | ASPIRIN. | ASPIRIN | 1 | Oral | 81 MG | 0 | 81 | MG | TABLET | QD | ||||||
123648163 | 12364816 | 19 | C | CALCIUM + VITAMIN D3 | CALCIUMCHOLECALCIFEROL | 1 | Oral | 1 ANZ | 0 | TABLET | QD |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
123648163 | 12364816 | 1 | Asthma |
123648163 | 12364816 | 2 | Chronic obstructive pulmonary disease |
123648163 | 12364816 | 3 | Dyspnoea |
123648163 | 12364816 | 4 | Blood cholesterol increased |
123648163 | 12364816 | 5 | Hypertension |
123648163 | 12364816 | 6 | Gastrooesophageal reflux disease |
123648163 | 12364816 | 7 | Diabetes mellitus |
123648163 | 12364816 | 8 | Type 2 diabetes mellitus |
123648163 | 12364816 | 9 | Diabetes mellitus |
123648163 | 12364816 | 10 | Hypothyroidism |
123648163 | 12364816 | 11 | Supplementation therapy |
123648163 | 12364816 | 12 | Supplementation therapy |
123648163 | 12364816 | 13 | Product used for unknown indication |
123648163 | 12364816 | 14 | Supplementation therapy |
123648163 | 12364816 | 15 | Supplementation therapy |
123648163 | 12364816 | 16 | Supplementation therapy |
123648163 | 12364816 | 17 | Hypersensitivity |
123648163 | 12364816 | 18 | Sensation of blood flow |
123648163 | 12364816 | 19 | Supplementation therapy |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
123648163 | 12364816 | HO |
123648163 | 12364816 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
123648163 | 12364816 | Angiopathy | |
123648163 | 12364816 | Apnoea | |
123648163 | 12364816 | Arthralgia | |
123648163 | 12364816 | Back disorder | |
123648163 | 12364816 | Back pain | |
123648163 | 12364816 | Bedridden | |
123648163 | 12364816 | Drug ineffective | |
123648163 | 12364816 | Fall | |
123648163 | 12364816 | Feeling abnormal | |
123648163 | 12364816 | Impaired quality of life | |
123648163 | 12364816 | Joint injury | |
123648163 | 12364816 | Limb discomfort | |
123648163 | 12364816 | Loss of consciousness | |
123648163 | 12364816 | Meniscus injury | |
123648163 | 12364816 | Nightmare | |
123648163 | 12364816 | Off label use | |
123648163 | 12364816 | Oxygen saturation decreased | |
123648163 | 12364816 | Pain | |
123648163 | 12364816 | Renal disorder | |
123648163 | 12364816 | Respiratory disorder | |
123648163 | 12364816 | Sciatica | |
123648163 | 12364816 | Sight disability | |
123648163 | 12364816 | Sleep apnoea syndrome | |
123648163 | 12364816 | Suicide attempt | |
123648163 | 12364816 | Unevaluable event | |
123648163 | 12364816 | Wheezing |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
123648163 | 12364816 | 1 | 2010 | 0 | ||
123648163 | 12364816 | 2 | 20150408 | 0 | ||
123648163 | 12364816 | 4 | 2014 | 0 | ||
123648163 | 12364816 | 5 | 2016 | 0 | ||
123648163 | 12364816 | 6 | 2001 | 0 | ||
123648163 | 12364816 | 7 | 2000 | 0 | ||
123648163 | 12364816 | 8 | 2003 | 0 | ||
123648163 | 12364816 | 9 | 2014 | 0 | ||
123648163 | 12364816 | 10 | 2006 | 0 |